This content is from: Home

Sandoz decision will encourage biosimilar PTAB proceedings

The Federal Circuit’s decision in Sandoz v Amgen will lead to biosimilar companies looking to use PTAB proceedings more to invalidate drug patents, because it is now harder for them to bring district court actions before filing biosimilar applications

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial